News | Golgi Neurosciences

Golgi news

29 August 2023

Golgi Neurosciences partners with CDD Vault to Drive Innovation in Neurodegenerative Disease Treatment

25 July 2023

Golgi Neurosciences and Breye Therapeutics announce successful closing of P2X7 receptor antagonist program transfer

5 July 2023

Golgi Neurosciences, a unique incubator to combat neurodegenerative disorders, starts operating

portfolio company news

26 January 2024

Golgi Neurosciences announces Breye Therapeutics to start Phase 1b/2a clinical trials

9 November 2023

Golgi Neurosciences celebrates Lario Therapeutics being awarded “Company Making a Difference 2023 Preclinical” by the Loulou Foundation

10 October 2023

Golgi Neurosciences announces Acousia Therapeutics receiving the approval for Phase 2 clinical trials

Golgi Neurosciences is a company-creator boutique with one ambitious mission: setting the ground to create therapies for the treatment of devasting neurodegenerative diseases by applying rigorously “Grounded Objectives Leading to a Great Impact (GOLGI)”.

Portfolio companies

Partnering projects

About the name

NEWS

golgi_neurosciences_map24

Golgi Neurosciences S.r.l.

Openzone - Via Ariosto, 21
20091 Bresso (Milan, Italy)
Share capital: 100.000 euro
PARTITA IVA: 12596130968
Numero REA: MI-2671780

Copyright © 2024 Golgi Neurosciences. All rights reserved | Privacy Policy | Cookie Policy | Disclaimer